LKT Labs

Biochemicals for Life Science Research

TG101348

TG101348

Product ID T2404
Cas No. 936091-26-8
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $102.30 In stock
5 mg $194.40 In stock
10 mg $295.40 In stock
Bulk Quote

Quicklinks

Description

TG101348 is an inhibitor of JAK2 that is currently in clinical trials as a potential treatment for myelofibrosis. TG101348 exhibits immunomodulatory and anticancer chemotherapeutic activities. In cells acquired from acute coronary syndrome patients, TG101348 decreases expression of Th17 cells and increases expression of Treg cells. TG101348 inhibits cellular proliferation of Hodgkin lymphoma cells and mediastinal large B-cell lymphoma cells; in vivo, this compound decreases tumor growth and increases survival. In animal models of myeloproliferative disease, TG101348 decreases hematocrit and leukocyte count, somewhat attenuating myelofibrosis.

Product Info

Cas No.

936091-26-8
Purity

≥98%
Formula

C27H36N6O3S
Formula Wt.

524.68
IUPAC Name

N-(2-Methyl-2-propanyl)-3-{[5-methyl-2-({4-[2-(1-pyrrolidinyl)ethoxy]phenyl}amino)-4-pyrimidinyl]amino}benzenesulfonamide
Synonym

SAR302503, Fedratinib
Solubility

DMSO 100 mg/mL (190.59 mM) Water Insoluble Ethanol Insoluble
Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

T2404 MSDS PDF
Info Sheet

T2404 Info Sheet PDF

References

Zheng Y, Wang Z, Deng L, et al. Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol. 2015 Jan 5;157(1):65-77. PMID: 25572535.

Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014 May 15;20(10):2674-83. PMID: 24610827.

Zhang M, Xu CR, Shamiyeh E, et al. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol. 2014 Apr;54(4):415-21. PMID: 24165976.

Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. PMID: 18394554.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M184790

    Metyrapone

    Steroidogenesis inhibitor

    ≥98%
  • O6845

    Orlistat

    Fatty acid synthase inhibitor.

    ≥98%
  • D3302

    Diaveridine Hydrochloride

    Coccidiostat; dihydrofolate reductase inhibitor...

    ≥98%
  • S8147

    Sulindac Sulfide

    NSAID; COX-1/2 and PDE inhibitor.

    ≥98%
  • R2510

    RGD-4C

    Peptide, used to deliver conjugated drugs to ce...

    ≥95%
  • H1662

    HER2/neu (654-662) GP2

    Peptide fragment of HER2/neu/erbB2 receptor.

    ≥95%
  • C104762

    CCT-245737

    CHK1 inhibitor.

    ≥98%
  • R2512

    RGD

    Tripeptide, binds cell surface integrins.

    ≥95%
  • K0038

    Kahweol Oleate

    Diterpene found in coffee beans.

    ≥98%
  • S2792

    SGX-523

    MET inhibitor.

    ≥98%
  • H9611

    Hydrocortisone

    Endogenous steroid hormone involved in stress s...

    ≥98%
  • L5993

    Loxoprofen Sodium Dihydrate

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • E4785

    Elvitegravir

    Integrase inhibitor.

    ≥98%
  • R1876

    all-trans-Retinol

    Diterpene component of vitamin A, differentiation ...
    ≥95%
  • B8071

    3-tert-Butyl-4-Hydroxyanisole

    BHA derivative, antioxidative food and cosmetic...

    ≥99% Single isomer
  • C1878

    Cetrimide

    Mixture of quaternary ammonium salts, cationic ...

    ≥98%
  • P333400

    PIK-75

    p110α inhibitor.

    ≥99%
  • E6356

    Epothilone D

    Microtubule depolymerization inhibitor.

    ≥98%
  • M1777

    R-(−)-α-Methylbenzyl Isothiocyanate

    ITC, used as chiral agent.

    ≥98%
  • P3440

    PIK-293

    p110δ PI3K inhibitor.

    ≥98%